Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clozapine: plasma levels and prolactin response.

Literature DB >> 6785813

Clozapine: plasma levels and prolactin response.

J M Kane, T B Cooper, E J Sachar, F S Halpern, S Bailine.

Abstract

Serial plasma clozapine levels and serum prolactin levels were determined in two schizophrenic patients receiving clozapine, a novel antipsychotic drug. Despite marked therapeutic response and substantial clozapine blood levels, prolactin levels obtained 11--12 h after the last oral dose were unaffected or only minimally elevated. This confirms previous evidence of clozapine's unusual characteristics.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1981 PMID： 6785813 DOI： 10.1007/BF00429215

Source DB: PubMed Journal: Psychopharmacology (Berl) ISSN： 0033-3158 Impact factor: 4.530

15 in total

1. Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency.

Authors: G Langer; E J Sachar; P H Gruen; F S Halpern
Journal: Nature Date: 1977-04-14 Impact factor: 49.962

2. Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding.

Authors: J E Leysen; W Gommeren; P M Laduron
Journal: Biochem Pharmacol Date: 1978-02-01 Impact factor: 5.858

3. A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood.

Authors: I Creese; S H Snyder
Journal: Nature Date: 1977-11-10 Impact factor: 49.962

4. A homologous radioimmunoassay for human prolactin.

Authors: Y N Sinha; F W Selby; U J Lewis; W P VanderLaan
Journal: J Clin Endocrinol Metab Date: 1973-03 Impact factor: 5.958

5. Clozapine--a potential antipsychotic agent without extrapyramidal manifestations.

Authors: R Matz; W Rick; H Thompson; S Gershon
Journal: Curr Ther Res Clin Exp Date: 1974-07

6. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia.

Authors: J Gerlach; P Koppelhus; E Helweg; A Monrad
Journal: Acta Psychiatr Scand Date: 1974 Impact factor: 6.392

7. [Effect profile of a chemically new broad spectrum neuroleptic of the dibenzo-diazepine group].

Authors: H Gross; E Langner
Journal: Wien Med Wochenschr Date: 1966-10-01

8. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.

Authors: N P Nair; S Lal; P Cervantes; R Yassa; H Guyda
Journal: Neuropsychobiology Date: 1979 Impact factor: 2.328

9. The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine (clozapine).

Authors: G Stille; H Lauener; E Eichenberger
Journal: Farmaco Prat Date: 1971-10

10. RMI-81,582, a novel antipsychotic drug.

Authors: M A Young; H Y Meltzer
Journal: Psychopharmacology (Berl) Date: 1980-01 Impact factor: 4.530

14 in total

Review 1. Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors: J A Lieberman; A Z Safferman
Journal: Psychiatr Q Date: 1992

2. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.

Authors: Jose de Leon; Francisco J Diaz; Richard C Josiassen; George M Simpson
Journal: Eur Arch Psychiatry Clin Neurosci Date: 2004-10 Impact factor: 5.270

Clozapine: plasma levels and prolactin response.

1. Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency.

2. Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding.

3. A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood.

4. A homologous radioimmunoassay for human prolactin.

5. Clozapine--a potential antipsychotic agent without extrapyramidal manifestations.

6. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia.

7. [Effect profile of a chemically new broad spectrum neuroleptic of the dibenzo-diazepine group].

8. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.

9. The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine (clozapine).

10. RMI-81,582, a novel antipsychotic drug.

Review 1. Clinical profile of clozapine: adverse reactions and agranulocytosis.

2. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.

Review 3. Basic biology of clozapine: electrophysiological and neuroendocrinological studies.

4. Clozapine--a new and different neuroleptic.

Review 5. Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential.

6. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Review 7. Schizophrenia and oestrogens--is there an association?

Review 8. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Review 9. Pharmacokinetics and pharmacodynamics of clozapine.

Review 10. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation.